UBS raised the firm’s price target on Kymera Therapeutics (KYMR) to $128 from $90 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics price target raised to $100 from $95 at Stephens
- Kymera: Expanding Degrader Pipeline and Early Clinical Validation Support Buy Rating and Favorable Risk‑Reward
- Kymera Therapeutics price target raised to $120 from $110 at Citi
- Kymera Therapeutics Signals Strong Momentum In Earnings Call
- Kymera’s KT-579 Enters First-in-Human Testing: What Early Trial Progress Means for Investors